Padcev-Keytruda will now join Bristol Myers Squibb’s Opdivo in the list of bladder cancer drugs available on the NHS.

The upcoming Clinical Trials in Rare Diseases conference will cover the most concerning challenges in rare disease research.

Precision immunology company Scipher Medicine has introduced the ClinicalTrialRank.com AI platform to the public.

A501, which was placed on hold due to a patient death, will now resume with a reduced dose and altered regimen.

The long-term data supports the drug’s progression into the HEALEY ALS Platform trial, with NUZ-001 dosing set to commence in Q4 2025. This will only begin, however, if the US Food and Drug ...